$CRISPR Th_老虎社区_美港股上老虎

Pharmyang
2018-07-17

$CRISPR Therapeutics AG(CRSP)$

crispr遭遇巨大挑战，短期内看空

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":220119,"tweetId":"220119","gmtCreate":1531765177374,"gmtModify":1704896927772,"author":{"id":3461771638976755,"idStr":"3461771638976755","authorId":3461771638976755,"authorIdStr":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":233,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>$CRISPR Therapeutics AG(CRSP)$ crispr遭遇巨大挑战，短期内看空</body></html>","htmlText":"<html><head></head><body>$CRISPR Therapeutics AG(CRSP)$ crispr遭遇巨大挑战，短期内看空</body></html>","text":"$CRISPR Therapeutics AG(CRSP)$ crispr遭遇巨大挑战，短期内看空","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/220119","repostId":0,"isVote":1,"tweetType":1,"viewCount":3500,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["CRSP"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":57,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}